Risk of heart failure may be lower with celecoxib than with other NSAID
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7452.1338-a (Published 03 June 2004) Cite this as: BMJ 2004;328:1338
- Barbara Kermode-Scott
- Toronto
The anti-inflammatory cyclo-oxygenase-2 (COX 2) inhibitor celecoxib may be associated with a lower risk of congestive heart failure in the elderly than other non-steroidal anti-inflammatory drugs (NSAIDs), a large new Canadian study has found.
This study, published online on 29 May in the Lancet (http://www.thelancet.com/), was funded by the Canadian Institutes of Health Research.
“Our findings suggest significant differences between non-selective NSAIDs and individual COX 2 inhibitors with respect to risk of admission for congestive heart failure,” said the study's lead author, Professor Muhammad Mamdani, assistant professor in clinical epidemiology and healthcare research, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.